| 包装 | 价格(元) |
| 10mg | 电议 |
| 50mg | 电议 |
Animal models | 10-week-old (25–28 g), male, C57BL/6 mice |
Preparation Method | The MPTP-treated and exposed mice received a conventional, single dose of MPTP hydrochloride for 5 consecutive days and were kept in single cages in a separate room (T/E group). |
Dosage form | 30 mg/kg/day, s.c. |
Applications | MPTP hydrochloride has been widely used for inducing Parkinsonism in a variety of laboratory animals, especially in mice. MPTP could cause substantial loss of TH immunoreactivity in the SNpc as well as a significant diminution of TH protein level in the substantia nigra and striatum. |
| 文献引用 | |
| 产品描述 | MPTP(1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a neurotoxic agent that is a precusor of MPP+ which is toxic to dopaminergic neurons and causes Parkinsonism. It is commonly used in research to induce Parkinson′s disease models in primates. TheMPTPneurotoxicity in humans is irreversible and the consequential clinical and neurochemical features closely resemble those of the idiopathic Parkinson’s disease.[1] In vivo analysis demonstrated that systemicMPTPtreatments could lead to parkinsonian. Animals developed moderate-to-severe parkinsonian signs, including a marked loss of spontaneous movements (akinesia), muscular rigidity, and severe postural instability.[2] Most of theMPTPand metabolites were excreted in the urine within the first hour after treatment.MPTPmetabolite found in the urine during the first hour after treatment isMPTPN-oxide. However,MPTPN-oxide and MPP+ may cause DA depletion only if injected directly into the neostriatum.[1] References: |
m.cnreagent.com